AKIGAI has secured a strategic partnership with investor Brynjar Forbergskog in a 20 MNOK funding round. We are privileged to have Brynjar join our mission:
“To make an EGFR-inhibitor available to as many neuropathicpain patients as possible, as quickly as possible.”
Brynjar Forbergskog brings experience and a strong track record in the Biotech segment. His support will play a key role in advancing AKIGAI’s preparations for a Phase III clinical trial in Complex Regional Pain Syndrome (CRPS).
CRPS is widely regarded as one of the most severe and debilitating pain conditions. To date, no drug has ever received FDA or EMA approval for this indication. However, we have seen frequent, dramatic and sustained effects from EGFR-inhibitors in CRPS patients. Our development candidate (AKI-007) has been granted orphan drug designation by both the FDA and EMA, reinforcing the promise of our approach.